Semaglutid na wan pɔpul mɛrɛsin fɔ mɛn tayp 2 dayabitis ɛn fɔ mek yu nɔ gɛt bɔku bɔku bɔdi. I de wok bay we i de falamakata di natura GLP-1 ɔmon fɔ mek di blɔd shuga rigul ɛn fɔ mek i nɔ want fɔ it. Di wan dɛn we FDA dɔn gri fɔ, lɛk Ozempic, Wegovy, ɛn Rybelsus, dɔn pruv se dɛn kin wok fɔ bɔku sik pipul dɛn.
כltu, kכmpawnd semaglutide de gi wan kכstכm sכlushכn fכ wan wan pipul dεm we dεn nid nכ de mit bay standad fכm dεm. Insay dis atikul, wi go tɔk bɔt wetin na kɔmpawnd sɛmaglutayd, wetin mek di wan dɛn we sik kin pik am, ɛn di prɔblɛm dɛn ɛn bɛnifit dɛn we i kin gɛt.
Kɔmpawnd sɛmaglutayd na pɔsin in yon mɛrɛsin we dɛn mek bay kɔmpawnd famasi dɛn pas famasi kɔmni dɛn. Wail di aktif ingridiεnt, semaglutide, de stil di sem lεk in kכmεshכnal fכmyuleshכn, kכmpawnd vεshכn dεm dεn kכstכm fכ mit di spεsifi k nid dεm fכ wan wan pasεnshכn dεm. Dɛn ajɔstmɛnt dɛn ya kin bi:
● Doz Modifications: Tayl di doz fɔ mit di pɔsin in tritmɛnt rikwaymɛnt.
● Ɔltɛr Administreshɔn Fɔm: Fɔ pripia ɔda we dɛn lɛk likwid fɔm ɔ we nɔ de injɛkshɔn (ɛgz., sɔblingwal ɔ nos sprɛy).
● Fɔ pul di tin dɛn we de mek pɔsin gɛt alɛji: Fɔ pul sɔm tin dɛn we nɔ de wok we kin mek sɔm sik pipul dɛn gɛt alɛji ɔ fil.
Nɔ lɛk kɔmɛshɔnal sɛmaglutayd prɔdak dɛm lɛk Ozempic, Wegovy, ɔ Rybelsus, kɔmpawnd semaglutayd nɔ gɛt FDA aprɔv. Dis min se i nɔ bin dɔn du di sem strɔng klinik tɛst fɔ sef, ifektiv, ɛn kwaliti we FDA-apruv mɛrɛsin dɛn fɔ go tru. Fɔseka dat, kɔmpawnd vɛshɔn dɛn nɔ kin mit di sem standad fɔ kɔnsistɛns ɛn rigyuletɔri ovasayt.
Di kɔmpawnd prɔses involv laysens famasi we de chenj ɔ jɔyn di tin dɛn we dɛn de yuz fɔ mek wan fɔmyulashɔn we fit di pɔsin in patikyula nid dɛn. Dɛn kɔstɔmayt vɛshɔn ya fɔ sɛmaglutayd kin tek sɔm kayn we dɛn, lɛk:
Kɔmpawnd de alaw di famasi fɔ mek sɛmaglutayd insay dos dɛn we nɔ de na kɔmɛshɔnal, we de mek i fayn fɔ di pasɛnt dɛn we nid mɔ ɔ smɔl pas wetin dɛn gi insay standad dos.
Fɔ di sik pipul dɛn we nɔ kin fil fayn fɔ injɛkshɔn ɔ we nɔ kin ebul fɔ swɛla pils, dɛn kin mek kɔmpawnd sɛmaglutayd fɔ mek i bi likwid, tablɛt we de ɔnda di langwej, ɔ sprɛy na in nos. Dɛn ɔda we ya kin gi di sikman dɛn tritmɛnt opshɔn dɛn we izi ɛn we pɔsin kin ebul fɔ gɛt.
Sɔm sik pipul dɛn kin fil fɔ sɔm tin dɛn we nɔ de wok (ɛgz., prɛzɛvɛtiv, stɛbyulayz, ɔ kɔla ɛjɛn) we dɛn kin si na kɔmɛshɔnal sɛmaglutayd. Kɔmpawnd de mek di famasi dɛn ebul fɔ pul ɔ chenj dɛn tin ya, ɛn dis kin mek di mɛrɛsin sef fɔ pipul dɛn we gɛt sɛnsitiv tin.
Bɔt bikɔs di FDA nɔ de rigul di kɔmpawnd mɛrɛsin dɛn di sem we lɛk di kɔmɛshɔnal prɔdak dɛn, pipul dɛn de wɔri bɔt di kɔnsistɛns ɛn sef we di kɔmpawnd sɛmaglutayd gɛt, mɔ bɔt di kɔntaminɛshɔn we kin kam, di kɔrɛkt doz, ɔ di yus fɔ tin dɛn we dɛn nɔ gri fɔ yuz. So, i impɔtant fɔ gɛt kɔmpawnd sɛmaglutayd frɔm famasi dɛn we gɛt gud nem, we gɛt laysens ɛn we de fala strikt sefty protɔkɔl dɛn.
Fɔmulashɔn |
Tɔk bɔt |
Ɔral Sɔlwɛshɔn |
Fɔ pasɛnt dɛn we nɔ kin ebul fɔ bia wit injɛkshɔn |
Sɔblingual |
Fɔ di pasɛnt dɛn we lɛk fɔm dɛn we nɔ gɛt injɛkshɔn |
Nasal Spray we dɛn kin yuz |
Ɔda we fɔ injɛkshɔn ɔ fɔmyulashɔn we dɛn kin tek bay mɔt |
Dɛn kin gi yu kɔmpawnd sɛmaglutayd fɔ sɔm rizin dɛn:
● Nɔ de: We di kɔmɛshɔnal sɛmaglutayd nɔ de.
● Kastamayzeshɔn: We di sikman dɛn nid sɔm patikyula doz ɔ fɔmyulashɔn dɛn we nɔ de na kɔmɛshɔnal prɔdak dɛn.
● Alɛji Manejmɛnt: Fɔ di wan dɛn we gɛt alɛji to tin dɛn we nɔ de wok na di kɔmɛshɔnal vɛshɔn dɛn.
● Fɔm dɛn we Nɔ De Injɛkshɔn: Fɔ di wan dɛn we nɔ lɛk fɔ injɛkt di mɛrɛsin.
Wan pan di praymar bɛnifit dɛm fɔ kɔmpawnd sɛmaglutayd na in kɔstɔmayshɔn fɔ mit spɛshal pasɛnt nid dɛm. Nɔ lɛk semaglutayd we FDA dɔn gri fɔ, we kin kam insay standad doz ɛn di we aw dɛn kin gi am (tipikli injɛkshɔn ɔ ɔral tablɛt), dɛn kin tayla kɔmpawnd semaglutayd insay dɛn we ya:
● Pɔsin in yon Doz: Sɔm sik pipul dɛn kin nid fɔ tek di doz we pas ɔ smɔl pas di wan dɛn we de na kɔmɛshɔnal vɛshɔn dɛn. Kɔmpawnd de alaw fɔ dɛn ajɔstmɛnt ya fɔ mek shɔ se di rayt tritmɛnt doz fɔ ɛni wan pan dɛn.
● Ɔda we dɛn fɔ gi am: Pan ɔl we dɛn kin injɛkt ɔ tek sɛmaglutayd bay mɔt, dɛn kin mek kɔmpawnd we dɛn mek am difrɛn we dɛn, lɛk tablɛt we dɛn kin yuz fɔ yuz am na di blɔk, sprɛy na in nos, ɔ ivin wata we dɛn kin yuz fɔ mek am. Dɛn ɔda we ya kin bɛnifit mɔ fɔ di wan dɛn we gɛt prɔblɛm wit injɛkshɔn ɔ swɛla pils, we kin gi mɔ fleksibiliti we dɛn de gi dɛn.
Insay 2023, di wɔl shɔt fɔ semaglutide bin apin, mɔ we bin afɛkt di brand dɛn we pipul dɛn sabi lɛk Ozempic ɛn Wegovy. Dɛn shɔt tɛm ya bin mek bɔku pasɛnt dɛn bin de luk fɔ ɔda tritmɛnt dɛn. Kɔmpawnd sɛmaglutayd bin bi sɔlvishɔn insay dɛn chalenj tɛm ya fɔ sɔm rizin dɛn:
● Big-Skel Prodakshɔn: We di FDA-apruv semaglutide nɔ de, dɛn kin alaw kɔmpawnd famasi dɛn fɔ prodyuz big batch dɛn fɔ semaglutide fɔ mit di pɔsin in dimand, fɔ mek shɔ se dɛn kɔntinyu fɔ trit am.
● Availability During Shortages: Compounding farmasi dɛn de ple impɔtant pat fɔ ful di gap insay di tɛm dɛn we kɔmɛshɔnal vɛshɔn fɔ semaglutide nɔ de, we de gi di sikman dɛn ɔda we we de ɛp dɛn fɔ manej dɛn wɛlbɔdi kɔndishɔn we nɔ go ambɔg dɛn.
Rizin fɔ Pik Kɔmpawnd Sɛmaglutid |
Ɛgzampul dɛn |
Drug Shortges |
Short fɔ Ozempic ɔ Wegovy |
Kastom Doz we dɛn kin yuz |
Di dos dɛn we ay ɔ smɔl pas di wan dɛn we dɛn kin gɛt na kɔmɛshɔn |
Di tin dɛn we de mɔna pɔsin wit alɛji |
Nɔ gɛt tin dɛn we de mek pɔsin nɔ pwɛl ɔ tin dɛn we de mek pɔsin kɔlɔ |
Di wan dɛn we gɛt alɛji to tin dɛn we nɔ de wok, lɛk tin dɛn we dɛn kin yuz fɔ mek tin dɛn we nɔ de pwɛl, day, ɔ tin dɛn we dɛn kin yuz fɔ mek tin dɛn we dɛn kin yuz fɔ mek sɛmaglutayd we dɛn kin sɛl, kin pik kɔmpawnd vɛshɔn dɛn. Famasi dɛn kin tayla dɛn fɔmyulashɔn ya fɔ avɔyd alɛrjens, we de gi wan opshɔn we sef fɔ di pasɛnt dɛn we gɛt sɛnsitiviti.
Wan pan di praymar kɔnsyusɔn wit kɔmpawnd sɛmaglutayd na di lɔk fɔ FDA aprɔval. Di FDA nɔ de tɛst kɔmpawnd mɛrɛsin fɔ si if dɛn sef ɛn if dɛn wok, nɔto lɛk di mɛrɛsin dɛn we dɛn kin sɛl. Dis min se kɔmpawnd sɛmaglutayd nɔ kin gi di sem garanti pan kwaliti, kɔnsistɛns, ɛn sef. Pan ɔl we dɛn kin mek kɔmpawnd sɛmaglutayd na laysens famasi, dɛn mɛrɛsin ya nɔ kin du di sem tɛst we dɛn kin du di wan dɛn we FDA dɔn gri fɔ.
pan ɔl we semaglutayd insɛf kin jɔs telɛret fayn, kɔmpawnd vɛshɔn dɛn kin mek ɔda risk dɛn bikɔs ɔf difrɛns pan fɔmyulashɔn, di we aw dɛn nɔ de gi am di rayt we, ɔ di kɔntaminɛshɔn we dɛn de pripia. Di sayd ifekt dɛm fɔ semaglutide, lɛk nɔs, dayarɛa, ɛn bɛlɛ at, kin apin wit ɔl tu di kɔmɛshɔnal ɛn kɔmpawnd vɛshɔn dɛm. Bɔt, kɔmpawnd sɛmaglutayd kin gɛt ɔda prɔblɛm dɛn, lɛk:
● Di Doz we Nɔ Kɔrɛkt: If dɛn chenj di kɔmpawnd, dat kin mek dɛn tek di mɛrɛsin pasmak ɔ nɔ tek di mɛrɛsin bɛtɛ.
● Kɔntaminɛshɔn: If dɛn nɔ fala di rayt hajɛns ɛn kɔmpawnd tɛknik dɛn, dɛn kin put bad bad tin dɛn insay di mɛrɛsin.
● Sɔl dɛn we dɛn nɔ gri fɔ: Sɔm kɔmpawnd vɛshɔn dɛn kin yuz sɛmaglutayd sɔl dɛn we dɛn nɔ gri fɔ, lɛk sɛmaglutayd sɔdiɔm ɔ sɛmaglutayd asɛtat, we dɛn nɔ bin dɔn tɛst fɔ si if i sef.
Denja |
Tɔk bɔt |
Di Doz we Nɔ Kɔrɛkt |
vεryabiliti in kכmpawnd sεmaglutayd amoun dεm kin mek dεn nכ kכnsistεnt dכz. |
Kɔntaminɛshɔn |
If dɛn nɔ du am fayn fɔ mek dɛn kɔmpawnd, dat kin mek dɛn gɛt baktri ɔ fɛns. |
Ingridiɛnt dɛn we dɛn nɔ gri fɔ yuz |
Sɔm kɔmpawnd famasi dɛn kin yuz sɛmaglutayd sɔlt dɛn we FDA nɔ gri fɔ. |
Fɔ mek dɛn nɔ gɛt dɛn prɔblɛm ya, di wan dɛn we sik fɔ mek shɔ se dɛn gɛt kɔmpawnd sɛmaglutayd nɔmɔ frɔm di stet laysens famasi dɛn we de fala strikt sefty gaydlayn dɛn. Di FDA de wach di ɔtsɔsing fasiliti dɛn bɔt dɛn nɔ de rigul wan wan kɔmpawnd famasi dɛn, we de mek i impɔtant fɔ mek di pasɛnt dɛn chɛk fɔ si if di famasi de fala gud manufakchurin prɔsis.
Kɔmpawnd semaglutide kin gɛt difrɛn inaktiv ingridiɛnt dɛn we yu kɔmpia am wit di wan dɛn we FDA dɔn gri fɔ lɛk Ozempic, Wegovy, ɔ Rybelsus. dis vεryushכn dεm na di εksipiεnt dεm (inactive ingredients) kin impεkt aw di bכdi de abzכp di drog כ aw i de intarakt wit כda mεdikeshכn dεm. Fɔ ɛgzampul, sɔm kɔmpawnd vɛshɔn dɛn kin yuz difrɛn tin dɛn we de mek di mɛrɛsin nɔ pwɛl, tin dɛn we de mek pɔsin tinap, ɔ tin dɛn we dɛn kin yuz fɔ ful-ɔp, we kin afɛkt di we aw di mɛrɛsin de wok ɔ mek i gɛt bad bad tin dɛn we dɛn nɔ bin de tink se go apin. Di kɔmɛshɔnal sɛmaglutayd, na di ɔda say, de yuz standad ingridiɛnt dɛn we dɛn dɔn tɛst tranga wan fɔ kɔnsistɛns ɛn fɔ wok.
Pan ɔl we FDA-apruv semaglutayd prodakt dɛn kin de insay injɛkshɔn ɔ ɔral tablɛt fɔm, kɔmpawnd semaglutayd de gi kɔstɔmayz fɔmyulashɔn dɛn we kin bɛtɛ fit ɛnibɔdi nid. Fɔ ɛgzampul, sɔm kɔmpawnd famasi dɛn kin pripia tablɛt dɛn we dɛn kin yuz fɔ mek dɛn nɔs ɔ sprɛy na dɛn nos as ɔda tin dɛn fɔ yuz pas injɛkshɔn ɔ pils. Dɛn fɔm ya we dɛn mek fɔ dɛnsɛf kin rili bɛnifit di wan dɛn we gɛt prɔblɛm wit injɛkshɔn ɔ swɛla pils, we kin mek dɛn ebul fɔ du mɔ ɛn izi fɔ gi dɛn. Bɔt bikɔs dɛn fɔmyulashɔn ya nɔ de na kɔmishɔn, dɛn nɔ kin shɔ bɔt aw dɛn go wok ɛn aw dɛn go kɔnsistɛns.
Pan ɔl we kɔmpawnd sɛmaglutayd gɛt di sem aktiv ingridiɛnt, semaglutayd, lɛk di kɔmɛshɔnal vɛshɔn dɛn, i gɛt ay levul fɔ nɔ shɔ bɔt aw i go wok ɛn sef. FDA-apruv semaglutide de go ɔnda bɔku klinik trial ɛn strɔng tɛst fɔ mek shɔ se ɔl tu sef ɛn efficacy bifo dɛn rilis am na di makit. Bɔt kɔmpawnd sɛmaglutayd nɔ gɛt di sem lɛvul fɔ skrutinyɔ. Dis min se pan ɔl we i kin gi di sem bɛnifit, no garanti nɔ de bɔt in sef prɔfayl, kɔnsistɛns, ɔ fɔ wok fɔ lɔng tɛm. Di kɔmpawnd prɔses dɛn kin difrɛn bitwin di famasi dɛm, we kin mek difrɛns pan kwaliti ɛn di bad bad tin dɛm we kin apin. So, i impɔtant fɔ mek di sik pipul dɛn wej di prɔblɛm dɛn ɛn bɛnifit dɛn we dɛn kin gɛt we dɛn de tink bɔt kɔmpawnd sɛmaglutayd.
Kכmpawnd semaglutide jεnarali mכr afɔdabul pas in kכmεshכnal kכwntεrpat dεm, we de frכm $250 to $500 fכ wan mכnt, dipכnt pan di fכmulashכn εn di tin dεm we dεn ad. Bɔt di kɔmpawnd vɛshɔn dɛn nɔ gɛt inshɔrans, so di wan dɛn we sik kin nid fɔ pe aut ɔf-poket fɔ dɛn mɛrɛsin ya.
Tin |
Ɛstimat Prays Rɛnj |
Besik Kompawnd Semaglutid we dɛn kɔl |
$250 - $400/mɔnt |
Kɔmpawnd wit Ɔda Ingridiɛnt dɛn (ɛgz., B12, B6) . |
$300 - $500/mɔnt |
Di Fi fɔ Kɔnsultɛshɔn |
$50 - $200 (wan tɛm) |
Bɔku pan di wan dɛn we de gi inshɔrans, lɛk Mɛdikal ɛn Mɛdikal ɛp, nɔ de kɔba di kɔmpawnd mɛrɛsin dɛn. So, di sik pipul dɛn nid fɔ rɛdi fɔ di tin dɛn we dɛn go spɛn fɔ pe fɔ dɛn, we kin difrɛn bay di say we dɛn de, di we aw dɛn de trit dɛn, ɛn aw dɛn kin trit dɛn ɔltɛm. I impɔtant fɔ chɛk if dɛn kin yuz Ɛlth Sɛvins Akɔn (HSA) ɔ Fleksibul Spɛndin Akɔn (FSA) fɔ kɔba sɔm pan di kɔst dɛn.
Dɛn nid fɔ gɛt prɛskrishɔn frɔm laysens wɛlbɔdi prɔvayda fɔ gɛt kɔmpawnd sɛmaglutayd. Dis kin mek shɔ se dɛn mek di mɛrɛsin fɔ di patikyula mɛrɛsin we di pɔsin nid, ɛn dis kin mek shɔ se i sef ɛn i wok fayn.
I rili impɔtant fɔ gɛt kɔmpawnd sɛmaglutayd nɔmɔ frɔm wan famasi we gɛt laysens na di stet. Dɛn de rigul di famasi dɛn we gɛt laysens ɛn dɛn fɔ fala strikt gaydlayn dɛn fɔ mek shɔ se di mɛrɛsin dɛn sef. Di pasɛnt dɛn fɔ kɔnfɔm se di famasi we dɛn de wok wit de fala ɔl di standad dɛn we di lɔ se.
Sɔm tɛlihɛlth savis dɛn naw de gi akses to kɔmpawnd sɛmaglutayd tru vayrɔyal kɔnsultɛshɔn wit wɛlbɔdi prɔvayda dɛn. Dɛn savis ya kin wok wit laysens kɔmpawnd famasi dɛm fɔ gi pasɛnt dɛn izi akses to kɔstɔmayz mɛrɛsin dɛm.
Compounded semaglutide de gi wan pɔsnalayz aprɔch fɔ pasɛnt dɛn we gɛt spɛshal mɛrɛsin nid, lɛk di wan dɛn we nid kɔstɔm doz ɔ fɔm dɛn we nɔto injɛkshɔn. Bɔt i kin kɛr risk bikɔs ɔf di FDA aprɔval we i nɔ gɛt, inklud di kɔntaminɛshɔn we kin apin ɛn di mistek dɛn we kin mek i nɔ tek di doz. I impɔtant fɔ mek di sik pipul dɛn tɔk to dɛn wɛlbɔdi prɔvayda fɔ no if kɔmpawnd sɛmaglutayd fayn. Fɔ pik famasi we gɛt laysens ɛn we gɛt gud nem rili impɔtant. Fɔ di wan dɛn we de luk fɔ ay kwaliti kɔmpawnd sɛmaglutayd, . Cocer PeptidesTM de gi wan rilibul sɔlvishɔn, we de mek shɔ se sef ɛn ifektiv fɔmyulashɔn fɔ ɛvri pasɛnt in nid.
A: Kɔmpawnd sɛmaglutayd na kɔstɔm-mɛd mɛrɛsin we gɛt di sem aktif ingridiɛnt lɛk kɔmɛshɔnal sɛmaglutayd bɔt dɛn tay am fɔ mit sɔm patikyula nid dɛn we di pɔsin nid.
A: Kɔmpawnd semaglutide nɔto FDA-apruv, we min se i nɔ dɔn du di sem sefty ɛn ɛfifishins tɛst lɛk standad semaglutide mɛrɛsin lɛk Ozempic ɔ Wegovy.
A: Di sik pipul dɛn kin pik kɔmpawnd sɛmaglutayd we kɔmɛshɔnal opshɔn nɔ de, ɔ we dɛn nid pɔsnalayz doz ɔ fɔm we nɔto injɛkshɔn.
A: Pan ɔl we na laysens famasi dɛn de mek kɔmpawnd semaglutide, i nɔ gɛt FDA aprɔval, we min se risk kin de lɛk di kɔrɛkt doz ɔ kɔntaminɛshɔn.
A: Di kɔst fɔ kɔmpawnd sɛmaglutayd kin kɔmɔt frɔm $250 to $500 fɔ wan mɔnt, i dipen pan di fɔmyulashɔn ɛn ɔda tin dɛn we dɛn kin yuz fɔ mek am.
A: Bɔku pan di inshɔrans plan dɛn nɔ de kɔba kɔmpawnd mɛrɛsin dɛn, inklud kɔmpawnd sɛmaglutayd, so di sik pipul dɛn fɔ ɛkspɛkt fɔ pe aut-ɔf-ɔf-poket.
A: Yu go nid prɛskrishɔn frɔm laysens wɛlbɔdi prɔvayda fɔ gɛt kɔmpawnd sɛmaglutayd, we stet laysens famasi kin mek.
